Dopamine D2 receptor imaging in Gilles de la Tourette syndrome

Acta Neurol Scand. 2000 Mar;101(3):165-71. doi: 10.1034/j.1600-0404.2000.101003165.x.

Abstract

Objectives: To examine postsynaptic dopamine D2 receptors in Tourette syndrome (TS).

Material and methods: Seventeen patients and a control group were investigated using single photon emission computed tomography (SPECT) and iodobenzamide (123I-IBZM).

Results: In neuroleptic treated patients (n = 7) 123I-IBZM-binding was significantly reduced compared to both normal controls (P < 0.0001) and unmedicated patients (P < 0.001). In unmedicated patients (n = 10) mean binding ratio did not differ from that of control group. Patients in advanced stages of the disease, however, revealed significantly reduced relative striatal binding compared to patients in the early stages (P<0.005) and normal controls (P<0.0001).

Conclusion: The results lend further support to the hypothesis that the dopamine receptor is involved in TS pathology. During the natural course of the disease tics often improve in early adulthood. It is suggested that this spontaneous recovery from tics may be associated with reduced receptor binding capacity.

MeSH terms

  • Adolescent
  • Adult
  • Benzamides / metabolism
  • Benzamides / pharmacokinetics
  • Binding, Competitive / physiology
  • Child
  • Contrast Media
  • Corpus Striatum / diagnostic imaging*
  • Corpus Striatum / metabolism*
  • Dopamine Antagonists / therapeutic use
  • Female
  • Frontal Lobe / diagnostic imaging*
  • Frontal Lobe / metabolism*
  • Humans
  • Male
  • Middle Aged
  • Pimozide / therapeutic use
  • Pyrrolidines / metabolism
  • Pyrrolidines / pharmacokinetics
  • Receptors, Dopamine D2 / metabolism*
  • Severity of Illness Index
  • Tomography, Emission-Computed, Single-Photon*
  • Tourette Syndrome / diagnosis*
  • Tourette Syndrome / drug therapy
  • Tourette Syndrome / metabolism*

Substances

  • Benzamides
  • Contrast Media
  • Dopamine Antagonists
  • Pyrrolidines
  • Receptors, Dopamine D2
  • Pimozide
  • 3-iodo-2-hydroxy-6-methoxy-N-((1-ethyl-2-pyrrolidinyl)methyl)benzamide